Improved Care for Patients with Moderate-to-Severe Asthma: Reflecting on Errors and Missed Opportunities

Program Overview

The goal of this activity is to foster recognition of missed opportunities and suboptimal care among patients with moderate-to-severe asthma, thereby helping clinicians who treat these patients to examine best practices for management.

Credit Expired

CE Credit Expired

Expires: December 30, 2020

Target Audience

The target audience for this activity is allergy/immunology and pulmonology physicians practicing outside of the United States, who manage patients with moderate-to-severe asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Distinguish between the different types of asthma based on underlying pathophysiology and biomarkers of disease in order to make personalized treatment decisions
Identify patients with poorly-controlled or difficult-to-treat asthma who are eligible for step-up therapies, including new and emerging biologics
Incorporate new and emerging targeted biologics into the management of patients with severe or poorly-controlled asthma, when appropriate

Activity Faculty

Ratko Djukanovic, MD, DM, FRCP (Chair)

Professor, Medicine
Director, Southampton NIHR Respiratory Biomedical Research Unit
Director, NIHR Southampton Centre for Biomedical Research
Southampton, UK

Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP

Thomas H. Davis Chair, Pulmonary Medicine
Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases
Professor, Internal Medicine, Pediatrics and Translational Science
Wake Forest Baptist Health
Winston-Salem, NC

Michael E. Wechsler, MD, MMSc

Co-Director, The Cohen Family Asthma Institute
Professor, Department of Medicine
National Jewish Health
Denver, CO

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Featured RMEI CE Activities

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

Privacy | Terms of Use